Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

L19IL2/L19TNF in Pazienti con Carcinoma Squamocellulare Cutaneo

12 novembre 2026 aggiornato da: Philogen S.p.A.

Uno Studio di Fase 2 sull'Amministrazione Intratumorale di L19IL2/L19TNF in Pazienti con Carcinoma Squamocellulare Cutaneo Localmente Avanzato in Progressione o Intolleranti al Trattamento Sistemico

Open-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to Immune Checkpoint Inhibitor (ICI). The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

Tumor Assessment (TA) visits will be performed at Week 8 (Day 50 from the beginning of treatment), Week 12 (Day 78), and then every 8 weeks for the first year of Follow-up (FU). During second and third years of FU, TA visits will be performed every 12 Weeks. In case a response (CR, PR) or stable disease is observed, a confirmatory assessment of the tumor response will be performed 4 weeks after the TA visit, when the response was first recorded.

Confirmation of response will be assessed by histopathological analysis of specimens from the skin treated area by multiple punch biopsies. Confirmation of tumor responses will be centrally reviewed by an independent committee (Independent Central Review, ICR).

Patients will be followed for overall survival (OS) after a relapse or progression, and any further treatment given will be recorded until LPLV. Phone contact or any other documented contact with the patient will be recorded every 6 months for OS assessment from treatment start until the death of the patient, withdrawal of consent or until study completion (LPLV).

L19IL2/L19TNF will be administered to eligible patients under the supervision of the investigator or identified sub-investigator(s). Patients will receive intratumoral administrations of L19IL2/L19TNF into injectable cutaneous, subcutaneous tumors and nodal or in transit metastasis once weekly for up to 4 weeks. On the day of each treatment visit, all tumors to be injected should be measured and recorded (using caliper/ruler for cutaneous lesions and/or ultrasound for subcutaneous lesions). The recommended volume to be injected into the tumor(s) is dependent on the size of the lesion(s). The maximum dose to be administered in a single treatment visit is: 13 MioIU L19IL2 + 0.4 mg L19TNF. It is recommended that each lesion should receive the maximum amount possible to inject due to tumor properties at each visit.

Tipo di studio

Interventistico

Iscrizione (Stimato)

92

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Augsburg, Germania, 86179
        • Reclutamento
        • Universitaetsklinikum Augsburg
        • Investigatore principale:
          • Julia Welzel
      • Berlin, Germania, 10117
        • Reclutamento
        • Charite Universitaetsmedizin Berlin KöR
        • Investigatore principale:
          • Thomas Eigentler, Prof.
      • Essen, Germania, 45147
        • Reclutamento
        • Universitaetsklinikum Essen AöR
        • Investigatore principale:
          • Dirk Schadendorf, Prof.
      • Halle, Germania, 06120
        • Reclutamento
        • Universitaetsklinikum Halle (Saale) AöR
        • Investigatore principale:
          • Johannes Wohlrab, Prof.
      • Heidelberg, Germania, 69120
        • Reclutamento
        • Universitaetsklinikum Heidelberg AöR
        • Investigatore principale:
          • Jessica Hassel, Prof.
      • Kiel, Germania, 24105
        • Reclutamento
        • Universitaetsklinikum Schleswig-Holstein AöR
        • Investigatore principale:
          • Katharina Kahler, Prof.
      • Tübingen, Germania, 72076
        • Reclutamento
        • Universitaetsklinikum Tübingen AöR
        • Investigatore principale:
          • Lukas Flatz, Prof.
      • Athens, Grecia, 16121
        • Non ancora reclutamento
        • Andreas Syngros Hospital Of Venereal And Dermatological Diseases
        • Investigatore principale:
          • Alexandros Stratigos, Prof.
      • Naples, Italia, 80131
        • Reclutamento
        • IRCCS Istituto Nazionale Tumori Fondazione Pascale
        • Investigatore principale:
          • Paolo Ascierto, Prof.
      • Roma, Italia, 00168
        • Reclutamento
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • Investigatore principale:
          • Ketty Peris, Prof.
      • Rozzano, Italia, 20089
        • Reclutamento
        • Humanitas Mirasole S.p.A.
        • Investigatore principale:
          • Paolo Bossi, Prof.
      • Siena, Italia, 53100
        • Reclutamento
        • Azienda Ospedaliero-Universitaria Senese
        • Investigatore principale:
          • Annamaria Di Giacomo, Prof.
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Hospital Clinic De Barcelona
        • Investigatore principale:
          • Augustin Toll Abello
    • California
      • Orange, California, Stati Uniti, 92868-3201
        • Reclutamento
        • UC Irvine Health- Chao Family Comprehensive Cancer Center
        • Investigatore principale:
          • Maki MD Yamamoto
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Winship Cancer Institute, Emory University
        • Investigatore principale:
          • Michael C. Lowe, MD
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana-Farber Cancer Institute
        • Investigatore principale:
          • Emily Ruiz, MD
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Investigatore principale:
          • Melodi J Whitley, MD
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
        • Non ancora reclutamento
        • The Ohio State University Wexner Medical Center Clinical Laboratories
        • Investigatore principale:
          • Carlo Contreras, MD
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • The University of Texas MD Anderson Cancer Center
        • Investigatore principale:
          • Michael R Migden, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients must have histologically documented, locally advanced cSCC.
  • Patients must have at least one injectable and measurable cutaneous or subcutaneous lesion.
  • Patients must have locally advanced cSCC that has progressed on or cannot tolerate ICI treatment (adjuvant or first line) as assessed by a local multidisciplinary tumor board.
  • Patients with nodal, regional or in transit injectable cSCC lesions.
  • Patients must be willing to provide tissue from a core or excisional biopsy of a tumor lesion at screening and for confirmation of Objective Response or Stable Disease.
  • Male or female patients, who are capable of giving consent, age ≥ 18 years.
  • ECOG Performance Status/WHO Performance Status ≤ 2.
  • Hemoglobin > 10.0 g/dL.
  • Platelets > 100 x 109/L.
  • ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN).
  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
  • Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomised partner.
  • Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  • Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated basal cell carcinoma of the skin (surgically removed at least 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study.
  • Radiation therapy on the tumor sites in the 4 weeks prior to study drug administration.
  • Current topical or systemic chemotherapy, immunotherapy.
  • Presence of visceral metastasis.
  • disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris, inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
  • Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
  • Known arterial aneurysms.
  • Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2.
  • INR > 3.
  • Uncontrolled hypertension.
  • Known uncontrolled coagulopathy or bleeding disorder.
  • Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  • Moderate to severe respiratory failure.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Patients have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
  • Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
  • Pregnancy or breast-feeding.
  • Ischemic peripheral vascular disease (Grade IIb-IV).
  • Severe diabetic retinopathy.
  • Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  • Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression.
  • Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment

the patients will receive multiple intratumoral administrations of a mixture of L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks.

intratumoral administrations

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Response Rate (BORR)
Lasso di tempo: From enrollment up to a maximum of 160 weeks after the start of treatment

Best Overall Response Rate (BORR) as defined by the RECIST 1.1. criteria according to an Independent Central Review (ICR).

From enrollment up to a maximum of 160 weeks after the start of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 ottobre 2026

Completamento primario (Stimato)

1 febbraio 2031

Completamento dello studio (Stimato)

1 febbraio 2031

Date di iscrizione allo studio

Primo inviato

7 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2025

Primo Inserito (Effettivo)

14 novembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • PH-L19IL2TNFSCC-06/24
  • 2025-523231-19-00 (Ctis)
  • 2025 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi